The U.S. non-invasive cancer diagnostics market size accounted for USD 38.42 billion in 2025 and is predicted to increase from USD 42.58 billion in 2026 to approximately USD 107.53 billion by 2035, expanding at a CAGR of 10.84% from 2026 to 2035. Non-invasive cancer diagnostics is an advanced technology that offers unprecedented opportunities to increase early detection, improve diagnostic precision, and targeted treatment, which drives the growth of the market.
Non-invasive diagnostic technology involves processes that assess the body's internal condition without penetrating the skin or entering the body surgically. Non-invasive imaging processes, involving PET, MRI, and CT, are significant. With the applications of radioactive tracers, PET scans identify cancer and track the efficiency of treatment by identifying metabolic activity. These advanced imaging processes provide significant insights into cancer biology that support patients receiving more individualized treatments and achieving better results. Non-invasive imaging allows real-time tracking of cancer response to medicines and enables medical personnel to promptly adapt and enhance treatment plans. A non-invasive diagnostic test that analyses tumour-derived components in body fluids, most commonly blood, and other fluids such as urine, saliva, or cerebrospinal fluid, to identify cancer cells and cancer DNA (ctDNA).
In 2025, 2,041,910 new cancer cases and 618,120 cancer deaths are to occur in the United States.
Recent advances in volatile organic compounds (VOCs) have evolved as promising biomarkers for early disease identification, specifically for cancer. VOC profiles are related to metabolic substitutes that occur during disease progression. VOC analysis is significant in urine, sweat, and other types of biological samples. These VOCs serve as significant biomarkers for early detection, supporting differentiation between malignant and benign conditions, as well as among different stages of the disease. VOCs collected non-invasively in the breath are affordable, lack radiation exposure, and are increasingly precise.
By product type, the reagents & kits segment contributed the largest U.S. non-invasive cancer diagnostics market share of 49% in 2025. Reagents and kits allow non-invasive cancer detection by analysing circulating cancer biomarkers in body fluids, involving circulating cancer cells. Kits and reagents serve as crucial components in conducting diagnostic tests. These kits are custom-made to detect particular markers, mutations, or abnormalities related to different blood cancers.
By technology, the next-generation sequencing (NGS) segment contributed the largest market share of 28%. NGS allows comprehensive genomic profiling of tumours, detecting genetic modifications that drive cancer progression and enabling targeted treatment plans targeting specific mutations, therefore enhancing patient outcomes. Next-generation sequencing (NGS) has evolved as a significant technology in the sector of oncology.
By cancer type, the breast cancer segment held a significant share of 24% in the U.S. non-invasive cancer diagnostics market, as breast cancer diagnosis significantly improves prognosis and long-term survival rates. Different methods, involving sensors, imaging, and molecular biotechnology, have been developed to ease early identification. Non-invasive biomarkers are more convenient and enable prior identification of breast cancer.
By application, the early cancer screening segment contributed the largest market share of 33%. Early cancer detection enhances survival rates and simplifies behaviour. Early detection via cancer screening provides a multitude of advantages, both for patients and at the societal level. Early-stage cancers can be treated with localized surgeries, negligible interventions, or targeted therapies, completely avoiding the exhausting regimens.
By end user, the hospitals segment contributed the largest market share of 36%, as non-invasive testing has evolved as a safer, more effective strategy for diagnostics, providing patients and healthcare providers with substitutes to invasive procedures. Non-invasive tests do not require needles, anesthesia, or incisions, so they pose reduced challenges to patients of all ages and healthcare conditions.
Leading companies in the U.S. non-invasive cancer diagnostics market include F. Hoffmann-La Roche, GRAIL, Illumina, and Thermo Fisher Scientific. Meanwhile, F. Hoffmann-La Roche, U.S. hub driving molecular diagnostics, tissue-driven tests, and blood-based cancer identification services. GRAIL significantly focuses on multi-cancer early detection (MCED). Illumina offers the sequencing technology and platforms that major diagnostic organizations and laboratories use to analyse cell-free DNA. Thermo Fisher Scientific, it supplies high-throughput tools, reagents, and analytical software that power clinical labs performing non-invasive genetic testing.
By Product Type
By Therapeutic Area
By Cancer User
By Sample Type
By Application
By End User
